Showing 31-40 of 574 results for "".
- Simulated Patient Encounter Part of Summer AAD Programhttps://practicaldermatology.com/news/simulated-patient-encounter-part-of-summer-aad-program/2458888/Simulated patient encounters have come to the American Academy of Dermatology's summer meeting, offering a unique, hands-on educational experience for attendees. Speaking to Seemal Desai, MD for DermTube.com's coverage of the 2015 Summer Meeting of the AAD in New York City, Kanade Shinkai
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- Joseph R. Williams Becomes Vice President of Global Marketing for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140326-joseph_r_williams_becomes_vice_president_of_global_marketing_for_caliber_imaging__diagnostics/2459292/Caliber Imaging & Diagnostics named Joseph R. Williams Vice President of Global Marketing. Williams past experience led him to this new position. Previously, he was Director of Market Development at AxsunTechnologies/Volcano Corporation, Senior Director of Global Marketing-Neurosurgery Di
- Galderma Ups Its Aesthetic R&D Gamehttps://practicaldermatology.com/news/galderma-ups-their-aesthetic-r-d-game/2457570/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and
- WCD News: Experts Excited About Ornovi’s Next Generation JAK Inhibitorhttps://practicaldermatology.com/news/wcd-news-experts-excited-about-ornovis-next-generation-jak-inhibitor/2461833/Ornovi's OR-101 is a highly selective next generation JAK3-ITK inhibitor with potentially a better safety profile than JAK inhibitors currently on the market, according to a presentation at the 25th World Congress of Dermatology Meeting 2023 in Singapore. Seemal Desa
- SmartGraft Taps Industry Vet as New EVPhttps://practicaldermatology.com/news/smartgraft-taps-new-evp/2458031/Joseph R. Brown is the new Executive Vice President for SmartGraft®, a minimally invasive hair restoration
- ZELTIQ Receives FDA Clearance to Treat Submental Fat With Coolsculpting Procedurehttps://practicaldermatology.com/news/zeltiq-receives-fda-clearance-to-treat-submental-fat-with-coolsculpting-procedure/2458855/The FDA granted an expanded clearance for ZELTIQ(R) Aesthetics, Inc.’s Coolsculpting procedure, paving the way for the introduction of the new, CoolMini(TM) applicator, which is designed to treat smaller pockets of fat, including the submental, or chin fat area. The CoolSculpting(R) procedu
- Congress Establishes New Caucus on Skin Cancerhttps://practicaldermatology.com/news/20130708-congress_establishes_new_caucus_on_skin_cancer/2459502/A new bipartisan Congressional Member Organization will address the growing epidemic of skin cancer among Americans. Led by representatives Jim Cooper (D-TN-5th), Carolyn Maloney (D-NY-12th), Peter Roskam (R-IL-6th), and Charlie Dent (R-PA-15th), the caucus will support legislative activities and pr
- Rodan & Fields Takes on Teen Acne with Spotlesshttps://practicaldermatology.com/news/rodan-fields-takes-on-teen-acne-with-spotless/2459898/Rodan & Fields is launching Spotless, a patent-pending teen and young adult acne solution. The company is also updating its Unblemish R
- Consensus IDs Gaps in Atopic Dermatitis Skin Modelshttps://practicaldermatology.com/news/consensus-ids-gaps-in-atopic-dermatitis-skin-models/2488670/A 2026 expert consensus review published in the Journal of Investigative Dermatology examined the advantages and limitations of human-based in vitro models for atopic dermatitis (AD), identifying opportunities to improve preclinical research and reduce reliance on animal models. R